** Shares of Boston-based drug developer PepGen PEPG.O fall 9% to $2.56 premarket
** Company says it will temporarily pause mid-stage study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD)
** Says the study is paused until company can review results from patient group dosed with 10 mg/kg, which is expected during Q3
** DMD is a genetic disorder causing progressive muscle weakness and degeneration
** Company says no new safety issues related to PGN-EDO51 have been observed since the company's last safety update in January
** PEPG has fallen 83% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.